Latest Leadership And Governance News

WiseTech Global reported a robust FY25 with 14% revenue growth and a 17% rise in net profit, underpinned by a transformative $2.1 billion acquisition of e2open and strategic leadership changes.

McPherson’s Limited reported a 3.9% revenue decline to $139 million in FY25 amid a strategic shift to a pharmacy wholesaler model, posting a $15 million net loss but signaling moderate EBITDA growth ahead.

AdAlta Limited reported a reduced net loss of $4.5 million for FY2025 but flagged material uncertainty over its ability to continue as a going concern, with no dividends declared.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.

Pacific Current Group Limited reported a 3.3% decline in revenue and a 19% drop in underlying net profit after tax for FY25, alongside a major share buy-back and key portfolio restructurings.

Coles Group Limited reported modest growth in FY25 with $44.35 billion revenue and $1.08 billion net profit, underpinned by major supply chain investments and sustainability milestones. The company maintained dividends but faces ongoing legal challenges.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Ansell Limited reported robust FY25 results, driven by strong organic growth and the successful integration of Kimberly-Clark’s PPE business. The company also advanced its sustainability commitments and navigated tariff challenges with strategic pricing and sourcing.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Vysarn Limited reported a robust 40% increase in revenue to $106.5 million for FY2025, driven by key acquisitions and national expansion. The company’s profit after tax rose 34%, underscoring its growing footprint in Australia’s water infrastructure sector.

Cryosite Limited reported a 12% increase in revenue for FY25, driven by a 58% surge in its ultra-frozen and cryogenic segment, while deferring dividends to fund expansion plans.